RET M918T

RET M918T是髓质甲状腺癌（MTC）中最常见的躯体获得性突变。虽然目前还没有RET特异性抑制剂，但混杂激酶抑制剂在治疗RET过度活性方面取得了一些成功。然而，数据表明M918T突变可能导致耐药性，尤其是对血管内皮生长因子抑制剂莫特沙尼的耐药性。也有人认为RET M918T导致更具侵袭性的MTC，预后较差。
RET M918T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.